Clinical Trials Directory

Trials / Completed

CompletedNCT00231738

Protective Effect of EPA on Cardiovascular Events

Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
18,000 (planned)
Sponsor
Kobe University · Industry
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to test the hypothesis that the long-term use of highly (\>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.

Detailed description

Epidemiological studies from many countries including Finland, Italy, Japan, and The Netherlands have suggested that an increased intake of dietary fish or fish oil rich in the long-chain polyunsaturated n-3 fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), is inversely related to the risk of atherothrombotic diseases, in particular coronary artery disease (CAD). Results of many prospective observational cohort studies have found that diets rich in marine PUFAs may be protective against major cardiovascular events, including mortality from CAD, total cardiovascular death, all-cause mortality, and nonfatal myocardial infarction. To date, only a few studies have examined the effects of purified n-3 PUFA preparations in human subjects for short observation periods. The principle aim of the current study is to test the hypothesis that the long-term use of highly purified EPA(eicosapentaenoic acid: 1800mg/day), in addition to HMG-CoA reductase inhibitor, is effective in preventing cardiovascular events in Japanese patients with hypercholesterolemia.

Conditions

Interventions

TypeNameDescription
DRUGEicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)

Timeline

Start date
1996-11-01
Completion
2004-11-01
First posted
2005-10-04
Last updated
2015-11-20

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT00231738. Inclusion in this directory is not an endorsement.